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Abstract--This study was conducted to evaluate the empirical 
antibiotic therapy for febrile neutropenic patients, patterns of 
bacterial isolates and thei r drug resistance. 
Method: It was a retrospective study; data of the patients 
admitted to the university hospital from 1/1/2010 to 1/6/2012 was 
evaluated retrospectively. I C D-10 for Cancer patients was used 
to locate the H N of oncology patients. Then Data for all of these 
patients was reviewed according to our inclusion criteria to select 
our sample population. 
Results: A total of 272 microorganisms were isolated during the 
study period. G ram-negative bacteria accounted for 73.5% of 
organisms, while gram-positive organisms accounted for 21.6% 
of the total isolates. Ninety-three (48.9%) episodes were found to 
have inappropriate empirical antibiotic therapy. Bacterial 
isolates of 40 episodes were found to be resistant against the 
prescribed therapy, which is the 43.0% of the all episodes 
identified with inappropriate therapy.  Thirty episodes (32.25%) 
were found to have delay in the empirical therapy and for 
remaining 23 episodes 24.73% , no fungal therapy was prescribed 
after continuous episode of febrile neutropenia for 7 days.  
Conclusion: G ram-negative organisms are the predominant 
organisms in adult febrile neutropenic patients at our institute. 
Initial empirical therapy with piperacillin/tazobactam seems 
appropriate to cover most gram-negative pathogens, but 
considering high resistance of Klebsiella pneumoniae, other 
antipseudomonal b-lactam agent with no resistance should be 
considered.! If fever does not settle after 4-7 days of antibiotic 
treatment, anti-fungal therapy should be added. 
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I.           INTRODUCTION 
Neutropenia is the single most important 
predisposing factor to infection in the patient with cancer and 
infection is the most common cause of death in the theses 
patients. Weissv RV et al. (2003) conducted a retrospective 
study in 7 large states of America, and found that among the 
cancer identified in 537,606 cases. Infection and neutropenia 
were identified in 2,060,749 and 54,439 cases, respectively.1 
Studies have also reported that 48% to 60% of patients 
admitted with febrile neutropenia do have infection2. Febrile 
neutropenia is costly in terms of morbidity, mortality and 
associated financial expenditure. These infections can be life 
threatening and increase both the morbidity and mortality.36 
Patients with febrile neutropenia are at risk of life 
threatening sepsis, and therefore require immediate empirical 
antibiotic therapy. Infections in the neutropenic patient can be 
rapidly fatal if not managed properly. Appropriate and in time 
therapy is a key factor for the management of febrile 
neutropenic patients. Efforts should be done to improve the 
appropriateness of the empirical therapy or to find the other 
factors, which can influence the response of empirical therapy 
or patient clinical outcome.  
Selection of appropriate empirical therapy for febrile 
neutropenic patients is vital for good clinical outcome of the 
patient. Patterns of infection and resistance may vary time-to-
time and institution-to-institution. The choice of which 
antibiotic(s) to use needs to be established as a local policy, in 
consultation with the clinical teams managing patients on 
chemotherapy, and in accordance with local patterns of 
infection and resistance. 
Over the past decade there has been a considerable 
change in the spectrum and antibiotic susceptibility patterns of 
pathogens causing infection in febrile neutropenic patients. 
Additionally use of broad-spectrum antibiotics has resulted in 
emergence of multi drug resistant gram negative and gram-
positive bacteria. Therefore detection of epidemiological and 
resistance patterns shifts requires frequent monitoring and 
surveillance, particularly at centers treating large numbers of 
patients, where institutional differences can be substantial.   
The main objective of this study was to highlight FN 
as a serious complication of chemotherapy, evaluate the 
empirical antimicrobial therapy, and to have an insight into the 
spectrum and the trend in antimicrobial susceptibility pattern 
of febrile neutropenic patients.  
II.      MATERIALS AND METHODS  
This was a retrospective medical record review at 
Songklanagarind hospital, a large teaching hospital in southern 
Thailand.  Data for all the oncology patients diagnosed with 
febrile neutropenia during the decided study period from 
1/1/2010 to 1/6/2012 was reviewed. The Patient population 
consisted of adults (18years or above) with acute and chronic 
leukemia, lymphoma and solid tumors. Patients were included 
if they had fever greater than 38.3oC on one occasion or 
>38.0oC sustained for one hour and with an absolute 
neutrophil count of less than 500 cells  microL and had 
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positive cultures result. Inappropriate therapy was defined by 
three different criteria. 
 The bacterial isolate is not susceptible to the 
antimicrobial therapy. 
 Administration of empirical antibiotic after 24 hrs of 
detection of temperature >38.3oC. 
 Empirical therapy for fungus has not been started for 
patients having persistent fever after 4-7 days of 
antimicrobial therapy. 
SPSS Version 16 was used for data compilation and 
calculation. 
 
III.      RESULTS 
As described earlier it was a retrospective study, 
based on set criteria 580 potentially eligible patients were 
selected during the time period of 1/1/2010 to 1/6/2012. Two 
hundred and eight episodes of febrile neutropenia from 155 
patients were selected to be included in the study. The mean 
age of the final cohort was 46.2 (range, 18 - 78) years. Table 1 
shows the characteristics of all the patients included in the 
study. 
Among 208 episodes majority (151, 72.6%) were 
caused by gram-negative microorganisms. Gram-positive 
organisms were responsible of 26 episodes (12.4%). 20 
episodes (10.5%) were caused from multiple organisms 
including both gram positive & negative organisms. Eleven 
episodes (5.3%) were caused by organisms from fungal origin. 
In total 272 microorganisms were isolated from the 208 
episodes including all febrile episodes caused by single and 
multiple organisms. Out of 272, 200 (73.5%) were gram 
negative and 59 (21.6%) were considered to be gram positive. 
Among gram-negative bacteria, Escherichia coli with the 
percentage of 21.6% remained a predominant organisms and 
Enterococci species with percentage of 7.3 % was most 
frequently seen bacteria from gram-positive bacteria.  
Frequencies of different individual microorganism are given in 
table 2. 
Among febrile episodes from sterile sites, all 
episodes with the percentage of 139 (66.82%) were with 
bacteremia, and the remaining 69 (33.12%) were from 
unsterile sites. Among them urinary tract with the percentage 
of 40 19.23% was the second most site of infection, followed 
by gastrointestinal tract, chest and others with the percentages 
of 12 (5.78%) 11 (5.28%) and 6 (2.88%) respectively. 
 
TABLE I.  CHARACTERISTICS OF PATIENTS ADMITTED WITH 
FEBRILE NEUTROPENIA DURING STUDY TIME PERIOD. 
 
Character istics A ll (n) 
Number of episodes 208 
Gender F/M 128/80 
Type of cancer   
Solid 113 
L iquid 95 
vasopressors Use Yes/N O 73/135 
Neutropenia level  
Moderate >100microL 28 
Sever <100microL 180 
Bactermia Yes/No 140/68 
A K I* Yes/No 34/174 
*Acute kidney Injury 
 
Resistance patterns of isolated organisms during the 
study were also evaluated. E .coli and Klebsiella pneumoniae 
with the aggregate percentage of 41.1% (112) were the two 
most frequently isolated microorganisms. Out of total 112 
isolates 26 (23.2%) were found to produce extended spectrum 
betalactamase (ESBL). Imipenem and piperacillin/tazobactam 
were the most frequently used antibiotics and either of those 
were prescribed to all those 26 patients, and 9 isolates (34.6%) 
were found to be resistant to piperacillin/tazobactam while 
only 2 (7.6%) were found to be resistant to imipenem. 
Resistance patterns of most frequently isolated organisms are 
shown in table 3. 
According to the defined criteria 93 out of 208 
episodes (44.5%) were found to have inappropriate empirical 
antibiotic therapy. Bacterial isolates of 40 episodes were found 
to be resistant against the empiric prescribed therapy, which 
accounted for 43.0% of the all episodes indentified with 
inappropriate therapy. Thirty episodes (32.25%) were found to 
be delayed in the empirical therapy and for the remaining 23 
episodes (24.73%), no fungal therapy was prescribed after 
continuous episode of febrile neutropenia for 7 days.  
 
TABLE II.  SPECTRUM OF GRAM POSITIVE AND NEGATIVE 
ORGANISMS ISOLATED. 
 
Microorganism No. of isolates Percentage 
Escherichia coli 59 21.6% 
Klebsiella pneumoniae 53 19.4% 
Pseudomonas aeruginosa 38 13.9% 
Proteus mirabilis  13 4.7% 
Enterococci species 20 7.3% 
Streptococcus species 15 5.5% 
Staphylococcus aureus 10 3.6% 
Candida species 12 4.4% 
 
 
 
IV.      DISCUSSION 
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Bacterial etiology is often unidentified at the onset of 
infection. Awareness of the prevalence of causative bacteria in 
neutropenic patients with fever is important since timely 
adequate antimicrobial therapy is of vital importance. The 
epidemiology of bacteraemia in neutropenic cancer patients 
has changed7. Published studies by the International 
Antimicrobial Therapy Cooperative Group of the European 
Organization for Research and Treatment of Cancer (IATCG-
EORTC) have demonstrated the changing epidemiology over 
the past 3 decades. 
Gram-negative bacteria (GNB) caused approximately 
70% of monomicrobial bacteraemia in the 1970s, but the 
situation was entirely overturned by the late 1980s and 1990s, 
with gram-positive organisms causing approximately 70% of 
the episodes8-9. But recent studies show that trend is again 
changed to gram-negative organisms 10-11. The spectrum of 
bacterial isolates in our study is similar to what has been 
reported in other studies. Two hundred (73.5%) organisms 
were gram negative and 59 (21.6%) were gram-positive 
bacteria. Among gram-negative bacteria, E .coli with the 
percentage of 21.6% remained predominant organisms. 
Modification of antibacterial therapy is a reality in 
clinical practice in the treatment of febrile neutropenia. Many 
studies have reported various response rates to empirical 
therapy from 50 -70% 12. One of the reasons to low response 
to empirical therapy can be inappropriate therapy, so we have 
tried to evaluate the empirical antimicrobial therapy and found 
out that 93 (44.5%) patients were prescribed with 
inappropriate therapy. According to IDSA empirical 
antifungal coverage should be considered in patients who have 
persistent fever after 47 days of a broad-spectrum 
antibacterial regimen. Twenty-three patients (24.73%) were 
not prescribed with fungal therapy after continuous episode of 
febrile neutropenia for 7 days, in addition to changes in 
combination broad-spectrum antibiotics, starting antifungal 
therapy would be the appropriate response. 
Bacterial isolates of 40 patients (43.0%) were found 
to be resistant against the prescribed therapy. At our 
institution, piperacillin/tazobactam is considered as a 
favorable choice and it is one of the most commonly 
prescribed antibiotics to the febrile neutropenic patients, but 
we have found high resistance (24.5%) to 
piperacillin/tazobactam in Klebsiella pneumonia, which is the 
second most commonly found organism in our study. Other 
anti-pseudomonal beta-lactam agents, such as carbapenem 
(meropenem or imipenem) with no resistance should be 
considered. 
A large proportion of the patients were found to be 
prescribed with inappropriate therapy, but the issue of effect of 
inappropriate therapy on the clinical outcome of the patient is 
still need to be addressed, taking length of stay and mortality 
as a parameter for clinical outcome, we have planned to 
compare the data from the patients of this study. Episodes 
from both groups, with appropriate and inappropriate therapy 
will be included in the study.  
 
TABLE III.  RESISTANCE PATTERNS OF MOST 
FREQUENTLY ISOLATED ORGANISMS 
 
Antibiotic E .coli K . 
pneumoniae 
P. 
aeruginosa 
A N T IB I O T
I C 
Enterococci 
 n=5
9 
% n=5
3 
% n=3
8 
%  n=2
0 
% 
Imipenem 0 0 0 0 9 23.6
8 
Imipenem 7 35.
0 
E rtapenem 0 0 0 0 - - Ampicillin 6 30.
0 
Meropenem 1 1.69 0 0 5 13.1
5 
Gentamicin 7 35.
5 
Piperaci llin/ 
tazobactam 
2 3.38 13 24.5 3 7.89 Vancomycin 0 0 
Ceftazidime 15 25.4
2 
16 30.1 1 2.63 Penicillin 9 45.
0 
Ceft riaxone 15 25.4
2 
16 30.1 - - - - - 
Amikacin 0 0 0 0 0 0 - - - 
Ciprofloxaci
n 
23 38.9
8 
21 39.6
2 
2 5.26 - - - 
Gentamicin 9 15.2
5 
9 16.9
8 
1 2.63 - - - 
Cotrimoxaz
ole 
27 45.7
6 
23 43.3
9 
- - - - - 
Colistin 0 0 0 0 0 0 - - - 
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